Brickell Biotech, Inc., a development-stage pharmaceutical company focused on the development of innovative drug therapies for the treatment of skin diseases, announced a $7 million Series B financing round to fund new chemical entities in dermatology for indications including acne, atopic dermatitis, and hyperhidrosis. The Series B is led by a new strategic partner, AMOREPACIFIC, the largest cosmetic and aesthetics company in Korea. Also participating in this round are existing investors, including Palisade Concentrated Equity Partnership II, L.P., a private equity fund managed by Palisade Capital Management, L.L.C., and others. The funds from this financing round will be used to support the further development of novel compounds in Brickell's pipeline from pre-clinical proof of concept through clinical testing.